To appraise the clinical and cost-effectiveness of atezolizumab in combination with nab-paclitaxel and chemotherapy within its marketing authorisation for breast cancer.
 
Status In progress
Process TAG
ID number 1574

Provisional Schedule

Expected publication 15 December 2021

Timeline

Key events during the development of the guidance:

Date Update
07 February 2020 Please note that following on from advice received from the company this appraisal has now been scheduled into the work programme We anticipate that the appraisal will begin during early February 2021 when we will write to you about how you can get involved.
17 October 2019 In progress, Refered 05/12/2017
30 August 2019 Suspended, To appraise the clinical and cost-effectiveness of atezolizumab in combination with nab-paclitaxel and chemotherapy within its marketing authorisation for breast cancer.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance